Company intelligence / Profile preview

E25Bio

Cambridge, Massachusetts, United Statesgatesfoundation.org ↗

Ownership: Private
Development stage: Commercial

Overview

E25Bio has developed rapid point-of-care diagnostic tests that deliver results in under fifteen minutes. Their COVID‑19 test uses nanoparticle technology to detect viral antigens and was being evaluated for FDA Emergency Use Authorization. The company’s dengue and Zika tests use similar paper-based lateral flow platforms. Clinical validation studies were underway at hospitals to assess sensitivity and specificity.

Therapeutic areas: Infectious Diseases
Modalities: DeviceNanoparticle-based detection technologyPaper-based diagnostic device
Industry: Protein Biomarker Diagnostics

Partnerships

MIT Tata Center/MIT Energy Initiative/Tata Center funding supportmanufacturing partners in Massachusetts, UK, and IndiaKhosla Ventures as a key investor

Beyond the preview

Go deeper on E25Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E25Bio.

Explore the full profile